Startseite>>Signaling Pathways>> Cell Cycle/Checkpoint>> Wee1>>PD 166285 dihydrochloride

PD 166285 dihydrochloride

Katalog-Nr.GC50045

PD 166285 Dihydrochlorid, ein Substrat von P-gp, ist ein WEE1-Inhibitor und ein schwacher Myt1-Inhibitor mit IC50-Werten von 24 bzw. 72 nM. PD 166285 Dihydrochlorid weist einen IC50 von 3,433 μM fÜr Chk1 auf.

Products are for research use only. Not for human use. We do not sell to patients.

PD 166285 dihydrochloride Chemische Struktur

Cas No.: 212391-63-4

Größe Preis Lagerbestand Menge
1 mg
185,00 $
Auf Lager
10 mg
397,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Potent inhibitor of the tyrosine kinases c-Src, fibroblast growth factor receptor 1 (FGFR1), and platelet-derived growth factor receptor β (PDGFRβ) (IC50 values are 8.4, 39.3 and 98.3 nM respectively). Also inhibits the checkpoint kinases Wee1 and Myt1; abolishes Cdc2 phosphorylation in numerous tumor cell lines and abrogates the G2 checkpoint.

Panek et al (1997) In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. J.Pharmacol.Exp.Ther. 283 1433 PMID:9400019 |Wang et al (2001) Radiosensitization of p53 mutant cells by PD0166285, a novel G2 checkpoint abrogator. Cancer Res. 61 8211 PMID:11719452 |Hashimoto et al (2006) Cell cycle regulation by the Wee1 inhibitor PD0166285, Pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line. BMC Cancer 6 292 PMID:17177986

Bewertungen

Review for PD 166285 dihydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PD 166285 dihydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.